Asset profile
Ametinib
Small molecule
Evidence outlook · results not reported
NCT05754736 · Non-small Cell Lung Cancer
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT05754736: This is a single-arm, open-label study with no comparator group, so there is no way to know whether the combination performs better than existing treatments. Results on tumor response and progression-free survival have not yet been posted.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
102 competitors in this universe: 41 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 80 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ametinib: this drug | Phase 2 | Small molecule | EGFR | ||
| Gefitinib | Approved | Small molecule | EGFR | ||
| Lazertinib | Approved | Small molecule | EGFR | ||
| Osimertinib (Tagrisso) | Approved | Small molecule | EGFR | ||
| Sunvozertinib | Approved | Small molecule | EGFR | ||
| Alflutinib | Phase 3 | Small molecule | EGFR | ||
| Almonertinib | Phase 3 | Small molecule | EGFR | ||
| Befotertinib | Phase 3 | Small molecule | EGFR | ||
| BPI-7711 | Phase 3 | Small molecule | EGFR | ||
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | ||
| FHND9041 | Phase 3 | Small molecule | EGFR | ||
| Icotinib | Phase 3 | Small molecule | EGFR | ||
| JMT101 | Phase 3 | Monoclonal antibody | EGFR | ||
| Limertinib | Phase 3 | Small molecule | EGFR, EGFR T790M (resistant mutant, selective over wild-type EGFR) | ||
| PLB1004 | Phase 3 | Small molecule | EGFR | ||
| SH-1028 | Phase 3 | Small molecule | EGFR |
…and 87 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
35 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.